ASRT stock touches 52-week low at $0.64 amid market challenges

Published 04/04/2025, 15:38
ASRT stock touches 52-week low at $0.64 amid market challenges

Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock has reached a 52-week low, trading at $0.65, as investors navigate through a period of market volatility and industry-specific headwinds. According to InvestingPro analysis, the company maintains a solid gross profit margin of 68.61%, despite current challenges. This low point marks a significant drop for the specialty pharmaceutical company, which has been grappling with various challenges over the past year. With a current market capitalization of $61.94 million, the stock appears undervalued according to InvestingPro Fair Value metrics. The 1-year change data for the company, formerly known as Depomed , reflects a substantial decline of -31.77%, underscoring the downward pressure on the stock and the broader concerns affecting the sector. Investors are closely monitoring the company’s performance and strategic initiatives as they assess the potential for recovery or further declines in the stock’s value. Notably, analyst price targets range from $1.75 to $3.50, suggesting significant upside potential. For deeper insights and additional ProTips about ASRT, including comprehensive valuation analysis, access the full Pro Research Report on InvestingPro.

In other recent news, Assertio Holdings reported its fourth quarter 2024 earnings, which exceeded revenue expectations with $32.18 million, surpassing the forecasted $28.67 million. The company also reported a narrower-than-expected loss per share of $0.03, compared to the forecasted $0.04. Despite these positive results, H.C. Wainwright adjusted Assertio’s stock price target to $3.50 from $4.00, while maintaining a Buy rating. Assertio’s annual revenues reached approximately $125 million, surpassing initial estimates, but the company’s revenue guidance for 2025 is set between $108 million and $123 million, which is below expectations. Analysts from H.C. Wainwright suggest the conservative outlook may be due to slower sales growth for ROLVEDON and ongoing generic competition impacting INDOCIN. Assertio’s full-year net loss in 2024 was $0.23 per share, more significant than anticipated, with a projected net loss of $0.19 per share for 2025. The company is exploring strategic acquisitions, with its CEO indicating a likelihood of such events occurring.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.